Tyrosine
In clinical developmentAlso known as (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid, (S)-(-)-Tyrosine, (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid, (S)-3-(p-Hydroxyphenyl)alanine+41 more
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid, (S)-(-)-Tyrosine, (S)-2-Amino-3-(p-hydroxyphenyl)propionic acid, (S)-3-(p-Hydroxyphenyl)alanine, (S)-Tyrosine, (S)-alpha-amino-4-Hydroxybenzenepropanoic acid, 4-hydroxy-L-phenylalanine, Aminosyn 10%, Sulfite-Free, Aminosyn 3.5 % M, Sulfite Free, Aminosyn 8.5 % with Electrolytes, Sulfite-Free, Aminosyn 8.5%, Sulfite-Free, Aminosyn II 10 %, Aminosyn II 15%, Aminosyn II 8.5 % with Electrolytes, Sulfite-Free, Aminosyn II 8.5 %, Sulfite-Free, Aminosyn-HBC 7 %, Sulfite-Free, Aminosyn-PF 10 %, Sulfite-Free, Aminosyn-PF 7%, Clinisol 15, L-Tyrosin, L-Tyrosine, Plenamine, PremaSol, ProSol, Tirosina, Travasol 10, Travasol 10%, Trophamine, Trophamine 10 %, Trophamine 6 %, Tyr, Y, Clinimix 4.25/10, Clinimix 4.25/25, Clinimix 4.25/5, Clinimix 5/15, Clinimix 5/20, Clinimix 5/25, Clinimix E 2.75/5, Clinimix E 4.25/10, Clinimix E 4.25/5, Clinimix E 5/15, Clinimix E 5/20, Clinimix E 5/25, Tyrosinum.
Recent clinical, regulatory, research and industry developments relating to this drug.
Contribution of L-Tyrosine to Human Decision Making in Stressful Situations
Contribution of L-Tyrosine to Recovery From Operational Strain on Return From External Operation
The Precision Hypertension Care Study
Treatment of TNNT1-Myopathy With L-Tyrosine. A Double-blind, Placebo-controlled Crossover Trial.
L-Tyrosine Supplementation in Patients With Fibromyalgia
Oxidative damage is the earliest event in Alzheimer disease.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
The Precision Hypertension Care Study
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes4
Journals, researchers & institutions
- The Journal of neuroscience : the official journal of the Society for Neuroscience2
- European heart journal1
- Journal of neuropathology and experimental neurology1
- PloS one1
- The New England journal of medicine1
- Perry G2
- Smith MA2
- Aliev G1
- Atwood CS1
- Bäckhed F1
- Balraj EK1
- Beckman JS1
- Braunwald E1
- Institute of Pathology2
- and Thoracic Institute1
- Biomedical Innovation Academy1
- Brigham and Women's Hospital1
- Center for Microbiome & Human Health1
- Center for Regenerative Therapies1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across 2 of the same disease areas as Tyrosine in the shared literature.
Studied across the same disease area as Tyrosine in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials